Lysergide d-tartrate for generalized anxiety disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 11 Dec 2024: Trial started, NCT06741228
  2. 18 Dec 2024: Trial registered, NCT06741228

The trials

NCT05407064: A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

State
Completed
Phase
Phase 2
People
198 taking part
Started
24 Aug 2022
Primary completion
6 Oct 2023
Arms
Arm 2- 25 μg MM120, Arm 3- 50 μg MM120, Arm 4- 100 μg MM120, Arm 5- 200 μg MM120
Results
Posted on the registry
Papers
doi:10.1001/jama.2025.13481
  1. 7 Jun 2022: Trial registered
  2. 24 Aug 2022: Trial started
  3. 27 Nov 2023: Trial completed
  4. 20 Mar 2025: Trial results posted

NCT06741228: A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

State
Under way
Phase
Phase 3
People
214 taking part
Started
11 Dec 2024
Primary completion
15 Jul 2026
Arms
Arm 2 - 100µg DT120
Results
None posted
Papers
doi:10.1136/bmj-2024-081723
  1. 11 Dec 2024: Trial started
  2. 18 Dec 2024: Trial registered

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.